Skip Navigation


JAC Advance Access originally published online on November 3, 2006
Journal of Antimicrobial Chemotherapy 2007 59(1):97-101; doi:10.1093/jac/dkl459
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
59/1/97    most recent
dkl459v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lüthje, P.
Right arrow Articles by Schwarz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lüthje, P.
Right arrow Articles by Schwarz, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Molecular analysis of constitutively expressed erm(C) genes selected in vitro in the presence of the non-inducers pirlimycin, spiramycin and tylosin

Petra Lüthje and Stefan Schwarz*

Institut für Tierzucht, Bundesforschungsanstalt für Landwirtschaft (FAL) Höltystr. 10, 31535 Neustadt-Mariensee, Germany

Received 19 September 2006; returned 9 October 2006; revised 10 October 2006; accepted 16 October 2006


*Corresponding author. Tel: +49-5034-871-241; Fax: +49-5034-871-246; E-mail: stefan.schwarz{at}fal.de

Objectives: As known from other lincosamides and 16-membered macrolides, the antimicrobial agents pirlimycin, spiramycin and tylosin, which are frequently used for the therapy of bovine mastitis, cannot induce the expression of the resistance gene erm(C). The aim of this study was to confirm the ability of these three non-inducers to select for constitutively expressed erm(C) mutants in Staphylococcus aureus.

Methods: A S. aureus strain carrying an inducibly expressed erm(C) gene was incubated on agar plates containing inhibitory concentrations of each of the three antimicrobial agents. The erm(C) regulatory region of mutants obtained after overnight incubation was amplified by PCR; selected amplicons were sequenced and compared with the wild-type sequence.

Results: Mutants developed in the presence of each of the three antimicrobial agents. Constitutive expression of erm(C) was due to variations in the erm(C) regulatory region. A total of 10 different types of deletions ranging in size between 16 and 121 bp as well as 20 different types of duplications ranging between 24 and 602 bp were detected. The frequencies by which sequence alterations occurred as well as the types of alterations detected varied with regard to the antimicrobial agents used for selection.

Conclusions: All sequence alterations observed explained constitutive erm(C) gene expression by functional inactivation of translational attenuation. In order to prevent the development of constitutively resistant isolates under therapy, the results of this study support the recommendation not to use lincosamides or 16-membered macrolides for the control of staphylococcal infections caused by strains harbouring inducibly expressed erm(C) genes.

Keywords: Staphylococcus , macrolides , lincosamides , bovine mastitis , mutation , translational attenuator


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.